Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs

Table 3 Mean annual costs (SD) in Euros within different levels of SDAI disease activity

	Costs resource use	Treatment costs	Total direct costs	Costs sick leave	Costs work disability (HCA)	Costs work disability (FCA)
REM	€828.28 (2,491.24)	€539.64 (729.46)	€1,367.92 (2,621.94)	€1,285.2 (1,502.1)	€5,772.8 (3,388.7)	€917.5 (538.3)
LDA	€1,039.02 (2,561.41)	€603.93 (762.06)	€1,642.95 (2,644.7)	€1,874.2 (2,185.9)	€7,186.6 (4,864.9)	€1,142.1 (772.8)
MDA/HDA	€1,702.39 (3,500.74)	€637.85 (748.46)	€2,340.24 (3,686.89)	€3,291.9 (2,871.3)	€10,525.7 (6,129.2)	€1,672.5 (973.7)
P value	0.06	0.65	0.05	<0.01	<0.01	<0.01

FCA, friction cost approach; HCA, human capital approach; HDA, high disease activity; LDA, low disease activity; MDA, moderate disease activity; REM, remission.
Treatment costs include patients treated with biologic agents (overall, 36.2%. The distribution among different levels of disease activity was equal: REM, 32.2%; LDA, 36%; MDA/HDA, 39%).

ISSN: 1478-6362